Prime Medicine (PRME) Revenue (2024 - 2026)

Prime Medicine posted quarterly Revenue of $856000.0 for Q1 2026, down 41.13% year-on-year from $1.5 million in Q1 2025, and up 2.15% on a QoQ basis from $838000.0 in Q4 2025.

Prime Medicine (PRME) has 3 years of Revenue data on file, last reported at $856000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Revenue fell 41.13% year-over-year to $856000.0; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 4.89% YoY), and the FY2025 full-year result was $4.6 million, up 55.28% from the prior year.
  • Revenue for Q1 2026 stood at $856000.0, up from $838000.0 in the prior quarter.
  • Across five years, Revenue topped out at $2.2 million in Q4 2024 and bottomed at $209000.0 in Q3 2024.
  • The 3-year median for Revenue is $985500.0 (2025), against an average of $1.1 million.
  • Peak annual rise in Revenue reached 486.12% in 2025, while the deepest fall reached 61.61% in 2025.
  • A 3-year view of Revenue shows it stood at $2.2 million in 2024, then slumped by 61.61% to $838000.0 in 2025, then climbed by 2.15% to $856000.0 in 2026.
  • The last three Revenue figures came in at $856000.0 (Q1 2026), $838000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.17 Bn
10 Prime Medicine 601.24 Mn 601.24 Mn - 856,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 856,000.00
Dec 31, 2025 838,000.00
Sep 30, 2025 1.23 Mn
Jun 30, 2025 1.12 Mn
Mar 31, 2025 1.45 Mn
Dec 31, 2024 2.18 Mn
Sep 30, 2024 209,000.00
Mar 31, 2024 591,000.00